Literature DB >> 20214933

Development of potential antiviral strategy against coxsackievirus B4.

Eng Lee Tan1, Andrew Phui Yew Wong, Chit Laa Poh.   

Abstract

Coxsackievirus B4 (CVB4) can cause a broad range of diseases such as aseptic meningitis, meningoencephalitis, myocarditis, hepatitis, pancreatitis, gastroenteritis, necrotizing enterocolitis, pneumonia and sudden death in the neonates. CVB4 has also been implicated as a possible etiological agent for type 1 insulin dependent diabetes mellitus (IDDM). In this study, the possibility of RNA interference (RNAi) as a potential therapeutic approach to treat CVB4 infection was explored. The results showed that the Rhabdomyosarcoma (RD) cells treated with 19-mer siRNAs displayed high specificity against CVB4 replication without displaying any sign of target effects. The siRNA targeting the 3C(pro) region of CVB4 genome was also established to be the most effective in inhibition of CVB4 replication in RD cell line in a dosage dependent manner, indicating its potential to be developed as an antiviral strategy against CVB4. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20214933     DOI: 10.1016/j.virusres.2010.02.017

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  7 in total

1.  Complete genome sequence of a recombinant coxsackievirus B4 from a patient with a fatal case of hand, foot, and mouth disease in Guangxi, China.

Authors:  Y F Hu; J Du; R Zhao; Y Xue; Fan Yang; Qi Jin
Journal:  J Virol       Date:  2012-10       Impact factor: 5.103

Review 2.  Enterovirus infections of the central nervous system.

Authors:  Ross E Rhoades; Jenna M Tabor-Godwin; Ginger Tsueng; Ralph Feuer
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

3.  Exploration of panviral proteome: high-throughput cloning and functional implications in virus-host interactions.

Authors:  Xiaobo Yu; Xiaofang Bian; Andrea Throop; Lusheng Song; Lerys Del Moral; Jin Park; Catherine Seiler; Michael Fiacco; Jason Steel; Preston Hunter; Justin Saul; Jie Wang; Ji Qiu; James M Pipas; Joshua LaBaer
Journal:  Theranostics       Date:  2014-06-06       Impact factor: 11.556

Review 4.  Antiviral RNAi: translating science towards therapeutic success.

Authors:  Priya S Shah; David V Schaffer
Journal:  Pharm Res       Date:  2011-08-09       Impact factor: 4.200

5.  Suspected Virus-Inducing Severe Acute Respiratory Distress Syndrome Treated by Multimodal Therapy Including Extracorporeal Membrane Oxygenation and Immune Modulation Therapy.

Authors:  Saya Ikegami; Kei Jitsuiki; Hiroki Nagasawa; Ryota Nishio; Youichi Yanagawa
Journal:  Cureus       Date:  2020-06-22

6.  The highly conserved 5' untranslated region as an effective target towards the inhibition of Enterovirus 71 replication by unmodified and appropriate 2'-modified siRNAs.

Authors:  Jun-Xia Deng; Xiao-Jing Nie; Ying-Feng Lei; Chao-Feng Ma; Dong-Liang Xu; Biao Li; Zhi-Kai Xu; Guo-Cheng Zhang
Journal:  J Biomed Sci       Date:  2012-08-13       Impact factor: 8.410

7.  Characterisation of enterovirus 71 replication kinetics in human colorectal cell line, HT29.

Authors:  Yan Long Edmund Lui; Peter Timms; Louise Marie Hafner; Tuan Lin Tan; Kian Hwa Tan; Eng Lee Tan
Journal:  Springerplus       Date:  2013-06-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.